BMS Sees Growth Products’ Contributions To Total Revenue Increase In Q3

Camzyos, Breyanzi Sales Rose By Triple Digits

 
• By Mandy Jackson
  
Bristol's legacy products, including Eliquis and Revlimid, continue to add the most to total revenue (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Scrip